20/20 Biolabs, Inc.

20/20 Biolabs' OneTest multi-cancer early detection blood test has been selected for a firefighter cancer screening initiative in Vermont, partnering with National Diagnostic Services. This 12-month statewide program is anticipated to generate approximately $500,000 in testing revenues for 20/20 Biolabs from the first cohort of Vermont firefighters through the end of 2026, with options for renewal. This follows a successful program in Maryland, which is expected to generate over $500,000 this quarter, with over $400,000 reimbursed by the Maryland Department of Health. The company anticipates more states will establish similar dedicated funds for firefighter screening and expects to benefit from future Medicare coverage for MCEDs starting in 2028.

20/20 Biolabs, Inc. announced that its Board of Directors adopted an amendment to the company's Amended and Restated Bylaws. This amendment, effective May 19, 2026, reduces the quorum requirement for stockholder meetings from a majority of outstanding shares to one-third of outstanding shares. This change modifies the rights of security holders by altering the threshold for valid stockholder meetings.

20/20 Biolabs, Inc. announced it is developing contingency plans to establish Ebola and Hantavirus testing capabilities in its CAP-accredited CLIA laboratory. This initiative leverages the company's substantial experience from the COVID-19 pandemic, during which it processed over 400,000 clinical samples. The company is engaging with global PCR test kit developers and evaluating existing equipment to ensure readiness for potential public health needs, though this announcement does not imply immediate commercialization.

20/20 Biolabs, Inc. reported a net loss of $(2,174,836) for Q1 2026, an increase from $(764,577) in Q1 2025, with revenues decreasing to $353,375. The company significantly strengthened its capital structure by raising $5 million through the issuance of Series E convertible preferred stock and warrants. Additionally, all outstanding Series A, A-1, A-2, B, C, and D preferred stock, along with convertible debt, were converted into common stock, resulting in a shift from a stockholders' deficit to $2,552,886 in equity.

20/20 BioLabs reported Q1 2026 financial results with revenue of $0.4 million, a decrease from $0.6 million in Q1 2025, and a net loss of $2.2 million, up from $0.8 million in the prior year. Despite the decline in Q1 revenue due to timing of orders, the company significantly strengthened its cash position to $4.2 million as of March 31, 2026, following a $5.0 million private placement. Operational highlights include expected meaningful revenue growth from state-funded firefighter cancer screening programs starting in Q2 2026, the launch of OneTest for Longevity, and a distribution agreement with Evexia Diagnostics.

20/20 BioLabs reported its first quarter 2026 financial and operational results, highlighting a $5.0 million private placement that boosted cash to $4.2 million. While Q1 2026 revenue declined to $0.4 million from $0.6 million year-over-year, the company anticipates significant revenue growth from state-funded firefighter cancer screening programs beginning in Q2 2026. Strategic wins include a distribution agreement with Evexia Diagnostics, a CKD license with ROKIT Healthcare, and the commercial launch of OneTest for Longevity.

20/20 BioLabs, Inc. announced that its Chief Executive Officer, Jonathan Cohen, will attend the upcoming Sidoti Micro-Cap Virtual Conference on Wednesday, May 20, 2026. Mr. Cohen is scheduled to host a presentation from 3:15 PM ET to 3:45 PM ET and will also participate in one-on-one investor meetings. He will discuss the company's recent quarterly results, partnership and licensing activities, and plans for scaling the OneTest platform.

20/20 BioLabs, Inc. announced an exclusive, worldwide licensing agreement with the University of South Carolina to commercialize a patented algorithm. This technology analyzes changes in PSA levels over time to identify rapidly growing prostate tumors, enabling earlier detection even before standard PSA thresholds are met. The algorithm will be integrated into 20/20 BioLabs' OneTest for Cancer platform and offered to other clinical laboratories via SaaS licenses, supporting the company's mission to make early cancer detection more accessible. The company also anticipates joint research to develop similar algorithms for other cancer markers like CA 125 and CA 19.9.

20/20 Biolabs, Inc. (AIDX) announced a global amendment with Streeterville Capital, LLC, on April 23, 2026, significantly reducing the exercise price of its outstanding warrants. The exercise price for Warrants 1, 2, and 3 was lowered to $2.25 per share from their original prices of $8.00 and $11.42. The company maintains a 90-day termination right for the amendment.